Anthem still determining coverage policy for Biogen Alzheimer’s drug

The office building of health insurer Anthem is seen in Los Angeles, California February 5, 2015. Connecticut and New York prosecutors reached out to No. 2 U.S. health insurer Anthem Inc on Thursday, a day after the firm said it was a victim of a cyberattack that compromised data of tens of millions of people. REUTERS/Gus Ruelas (UNITED STATES – Tags: BUSINESS CRIME LAW HEALTH)

July 21 (Reuters) – Anthem Inc (ANTM.N) said on Wednesday it was closely watching for guidance from the U.S. Food and Drug Administration and all available clinical evidence on Biogen Inc’s (BIIB.O) Aduhelm to determine its coverage policy on the newly approved Alzheimer’s drug.

“As new information becomes available, we’re going to continue to evaluate it with our clinical experts,” Anthem Chief Executive Officer Gail Boudreaux said in a conference call.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.

Our Standards: The Thomson Reuters Trust Principles.

Source link

Leave a Reply